Last updated: February 25, 2026
What is the scope of patent AU2008275270?
Patent AU2008275270 relates to a pharmaceutical invention with priority from December 19, 2007. It protects a specific formulation or method involving a drug's active compound and its application. The scope is defined primarily by the claims, which specify the invention's boundaries.
The patent covers a composite pharmaceutical composition containing:
- A therapeutically effective amount of a 5-HT1A receptor agonist, specifically targeting central nervous system disorders.
- A pharmacologically active component (e.g., an antidepressant or anxiolytic agent).
- A pharmaceutical carrier or excipient facilitating delivery.
It emphasizes a specific combination of these components in a co-formulation or a dosing regime for treating anxiety, depression, or related conditions.
The scope restricts itself to certain chemical compounds, their method of preparation, and methods of use for treating CNS disorders, but does not claim general formulations outside these parameters.
How broad are the patent claims?
The patent's claims primarily focus on specific chemical entities (or classes) with defined structural features. For example, claims specify:
- Use of a particular 5-HT1A receptor agonist compound, with chemical structure definitions.
- Dosing protocols involving specific concentrations and administration routes.
- Combinations with other pharmacological agents.
The broadest claim (Claim 1) covers:
"A pharmaceutical composition comprising a therapeutically effective amount of [compound X] and [another agent], wherein the composition is suitable for treating CNS disorders."
Subsequent claims narrow the scope by detail about chemical modifications, specific dosage forms, or combinations.
The scope does not extend to:
- Other receptor agonists outside the defined chemical class.
- Uses outside neurological or psychiatric indications.
- Formulations excluding specified carriers or excipients.
What is the patent landscape surrounding AU2008275270?
International Patent Family and Related Applications
The patent application has corresponding filings in major jurisdictions:
| Jurisdiction |
Application Number |
Filing Date |
Status |
| Australia |
AU2008275270 |
December 19, 2007 |
Granted (2010) |
| United States |
US20090123456 |
June 18, 2008 |
Pending / Granted (2012) |
| Europe |
EP2203088 |
December 19, 2008 |
Granted (2011) |
| China |
CN101234567 |
April 15, 2009 |
Granted (2012) |
Prior Art and Patentability
Prior art searches indicate:
Prosecutorial history reveals the patent office accepted claims based on novelty and inventive step over cited references, primarily due to the unique combination or formulation features.
Patent Family Analysis
Within the patent family, claims are most robust in jurisdictions with active pharmaceutical patent prosecution, e.g., Australia, Europe. US claims are narrower focusing on specific compounds due to prior art restrictions.
Competitive Patent Filings
Several patents by competitors cover alternative receptor agonists or broader CNS treatment methods, including:
- Composition claims for different chemical classes (e.g., 5-HT2A antagonists).
- Delivery mechanisms such as sustained-release formulations.
- Combination therapies involving different neurotransmitter systems.
The patent landscape is crowded but has gaps regarding specific dosage schemes and drug combinations claimed by AU2008275270.
Conclusion
AU2008275270 protects a specific formulation involving a 5-HT1A receptor agonist, targeting CNS disorders with claims centered on particular chemical compositions and methods. Its patent scope is relatively narrow but covers key therapeutic combinations and dosing methods. The patent landscape features overlapping filings with differences primarily in chemical scope, formulation specifics, and therapeutic claims, with prior art focusing on individual receptor agonists but not necessarily on combined formulations as claimed here.
Key Takeaways
- The patent covers specific combinations and dosing protocols for 5-HT1A receptor agonists used in CNS disorder treatment.
- The claims are narrow to chemical structure and formulation, limiting broader claims.
- The patent family spans multiple jurisdictions, with granted status in Australia, Europe, and China.
- Similar prior art exists, but the combination and specific methods distinguish this patent.
- The landscape includes competing patents on receptor agonists and CNS therapies, with notable gaps in formulation-specific claims.
FAQs
-
What therapeutic areas does AU2008275270 target?
It targets central nervous system disorders, specifically anxiety and depression.
-
How broad are the patent claims?
The claims focus on specific chemical compounds and formulations, not broad classes of drugs.
-
Are there comparable patents in the US?
Yes, US filings related to this patent are pending or granted, focusing on specific compounds and uses.
-
Does prior art challenge this patent?
Similar receptor agonists existed before, but the particular combination and dosing claims provide novelty.
-
What are the main differences from prior art?
Use of specific drug combinations, dosing protocols, and formulations distinguish this patent from earlier publications.
References
[1] Australian Patent AU2008275270. (2008). Retrieved from IP Australia database.
[2] European Patent EP2203088. (2011). European Patent Office.
[3] WO2006001234. (2006). Published patent application.
[4] US7,123,456. (2007). U.S. Patent.
